References
- Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239–252.
- Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185–192.
- Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 2004; 51: 471–480.
- Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapyof transfusional haemosiderosis. Baillieres Clin Haematol 1994; 7: 919–940.
- Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26–36.
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74.
- Hays RD, Stewart AL. Sleep measures. In: Stewart AL. (ed) Measuring functioning and well-being. The medical outcomes study approach. Ware J. Durham and London: Duke University Press, 2007; 235–239.
- Leplège A, Ecosse E, Pouchot A, Coste J, Perneger T. Le questionnaire MOS SF-36. Manuel de Putilisateur et guide d'inter-pretation des scores. Paris: Estem, 2001.
- Leplège A, Ecosse E, Verdier A, Perneger TV. The French SF-36Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51: 1013–1023.
- Cappellini MD, Bejaoui M, Agaoglu L et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29: 909–917.
- Vichinsky E, Pakbaz Z, Onyekwere O et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol 2008; 119: 133–141.
- Caro JJ, Ward A, Green TC et al. Impact of thalassemia major on patients and their families. Acta Haematol 2002; 107: 150–157.
- Ward A, Caro H, Green TC et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3.
- Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qua/ Life Outcomes 2006; 4: 73.
- Scalone L, Mantovani LG, Krol M et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008; 24: 1905–1917.
- Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919–1929.
- Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemio-logical survey. Eur J Clin Pharmacol 2001; 56: 915–922.